drug_type
RELEVANT_DRUG
intervention_type
CAR T-cell therapy (cellular immunotherapy)
drug_description
Autologous, gene-modified T cells transduced with a lentiviral vector to express a human CD1a-specific chimeric antigen receptor (CAR) with CD3ζ signaling and costimulatory domains; upon binding CD1a on malignant T-ALL/LBL cells, the CAR T cells activate, proliferate, release cytokines, and mediate perforin/granzyme-dependent cytotoxicity in an HLA-independent manner.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally transduced to express a human CD1a-specific chimeric antigen receptor with CD3ζ signaling and costimulatory domains. Upon binding CD1a on malignant T-ALL/LBL cells, the CAR triggers HLA-independent T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of target cells.
drug_name
OC-1 (hCD1a-CAR T)
nct_id_drug_ref
NCT05679895